CEO of AlzeCure Pharma participates in Redeye's Alzheimer's event.

AlzeCure Pharma, a Swedish CNS drug developer, announces CEO Martin Jönsson's participation in Redeye's Alzheimer's event on Mar 21, 2024. The event will see a panel discussion with AlzeCure, Bioarctic, and Alizinova on their drug candidates' science, the remaining need for Alzheimer's treatments, and launching a new generation of drugs. AlzeCure specializes in small molecule drug candidates for Alzheimer's and pain, with several drug candidates in development.

March 14, 2024
5 Articles

Further Reading